Publication at Faculty of Physical Education and Sport, First Faculty of Medicine |
2016
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with marked immunological abnormalities including, among others, the survival of autoreactive B lymphocyte clones. These have become the target structures for biological agents that already have established their role In clinical practice.
Belimumab is the first biological approved In the indication of SLE in patients without active renal damage or those with neuropsychiatrie manifestations. The objective of the present work is to briefly characterise blologicals targeting B lymphocytes and their role in therapy of SLE.